Skip to content
Open access

Targeting NAT10 suppresses TFH responses and alleviates allergic asthma via an ac4C-TOX2 axis

Jul 2026 · bioRxiv · 0 citations
Biology

TL;DR

This work elucidates a central epitranscriptomic mechanism controlling T helper cell fate and humoral immunity, and nominates NAT10 as a potential therapeutic target for TFH-driven diseases.

Abstract

Chemical modifications of RNA, such as N4-acetylcytidine (ac⁴C), fine-tune gene expression, but their roles in cell fate determination within the immune system remain poorly understood. Here, we identify the RNA cytidine acetyltransferase NAT10 as a pivotal regulator of T follicular helper (TFH) cell differentiation and the germinal centre response. T cell-specific ablation of Nat10 in mice severely impaired TFH cell development, germinal centre formation, and antibody production following viral infection. Integrated epitranscriptomic and transcriptional profiling revealed that NAT10 deposits ac⁴C modifications on a cohort of mRNAs critical for immune function. We pinpointed the transcription factor TOX2 as a key downstream target, showing that ac⁴C modification within its mRNA coding sequence enhances both transcript stability and translation efficiency, thereby promoting TOX2 protein expression. Enforced TOX2 expression fully rescued the TFH differentiation defect in NAT10-deficient cells. This NAT10-ac⁴C-TOX2 axis is conserved in humans, where its activity correlates with the magnitude of vaccine-elicited TFH responses. Furthermore, we identified R428 as a potent NAT10 inhibitor and demonstrated that its administration could suppress pathogenic TFH responses and alleviate symptoms in a mouse model of allergic asthma. Our work elucidates a central epitranscriptomic mechanism controlling T helper cell fate and humoral immunity, and nominates NAT10 as a potential therapeutic target for TFH-driven diseases.

Read PDF

Similar papers

Sep 2026

Super-enhancer–driven SGK1 activates polyamine metabolism to promote autoimmune uveitis

Uveitis, a leading cause of blindness, is driven by dysregulated immune responses, particularly autoreactive T cells. Despite advances in understanding its pathogenesis, key regulatory mechanisms remain elusive. Here, we integrate the cleavage under targets and tagmentation (CUT&Tag) and single-cell RNA sequencing (scR...

He Li, Lei Zhu, Zhao-Huai Li et al. · 0 citations
Open access Aug 2026

Unconventional role of hydroxymethylglutaryl-CoA synthase 1 in driving pathogenic TH17 cell immunity and autoimmune diseases

This work unveils a noncanonical axis in which HMGCS1 sustains ER stress to license pTH17 differentiation during autoimmune responses, and thereby unveils a noncanonical axis in which pTH17 immunity and mitigates autoimmune disease in vivo are revealed.

Jie Sun, Ya-Li Lei, Huan-Huan Yang et al. · 0 citations
Review Open access Aug 2026

m6A modification in immune-cell inflammatory fate: from RNA fate regulation to therapeutic translation in inflammatory diseases

Inflammatory disease is sustained not only by immune activation but also by the failure of activated cells to terminate effector programs and return tissues to homeostasis. This review evaluates N6-methyladenosine (m6A) as a post-transcriptional regulator of that persistence. Rather than cataloguing diseases or classif...

Yi-Zhang Zhu, Shiye Yang, Lei Qin et al. · 0 citations
Open access Sep 2026

Myeloid STING-ZBP1 Axis Drives Atherosclerosis by Inducing Macrophage PANoptosis

The STING-ZBP1 signaling cascade is established as a central regulator of macrophage PANoptosis during atherogenesis and a previously unrecognized mechanism linking innate immune signaling to inflammatory cell death in atherosclerosis is uncovered, highlighting this pathway as a promising therapeutic target for atheros...

Hong Zhou, Yue-Qing Han, Danmei Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.